Go to the profile of Sphere Fluidics

Sphere Fluidics

 
  • + 44 (0) 1223 804200
  • Leaders
  • United Kingdom
Go to the profile of Jeannett Antonie Øverby
Jeannett Antonie Øverby

QuanteInfluencer, Recovery coach, Heart coach , Spirit & Spa

Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature

Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing. ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.
Aposense, an Israeli publicly-traded biopharmaceutical company (TASE: APOS), is focused on a novel and powerful natural energy resource: the membrane dipole potential, a recently-discovered voltage, measurable in every leaflet of any phospholipid membrane. The dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center. Excitingly, this electric potential, and its related internal membrane electric field (IMEF) have not been recruited to date for any medical application. Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of "energy mining" from the IMEF, and its translation into kinetic energy, for movement within the hydrophobic membrane core. Upon linkage to a cargo drug, this intra-mem¬brane movement of the MNMs can be utilized for energy-consuming tasks, such as enabling the delivery of siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing, or moving the drug into drug depot sites generated at the depths of the phospholipid membranes. In both scenarios, Aposense’s MNM are improving pivotal drug features.
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.
Go to the profile of Emma Pickup
Emma Pickup

Account Executive, Sciad Communications

SCIAD is a marketing and communications agency that works with businesses in science, tech, healthcare, biotech and other science and technology-based sectors. We use integrated communications to drive up reputations and increase website traffic, connecting with the audiences that matter most by maximising the power of the web.
Go to the profile of Debayan Bose
Debayan Bose

Student, Academia Sinica

Go to the profile of Kamal Yahoo!
Kamal Yahoo!

sales & marketing and HR manager at sedico, innovation corporation LTD

Go to the profile of Raveena Bhambra
Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.
Go to the profile of Jen Thoroughgood
Jen Thoroughgood

Former Head of Communities, Springer Nature

I'm no longer with Springer Nature so please send your community-related queries to communities@nature.com. Thanks!
Go to the profile of Jenefer Thoroughgood
Jenefer Thoroughgood

Managing Director, Thoroughly Good Consulting

For nearly 20 years, I've worked in the digital media sector, with hands-on experience in editorial, marketing, sales and R&D. I'm passionate about engaging and understanding customers to develop great content and products. Formerly Chief Product & Customer Officer at Zapnito, I'm now an advisor to the company.
Go to the profile of Claire Thompson
Claire Thompson

Global Manager, Business Development, Nature Publishing Group

I head up the business development team responsible for Nature's special partnering publications, BioPharma Dealmakers and MedTech Dealmakers, plus our series of associated webcasts. The team and I take a highly consultative approach to ensure that the individual business development needs of all the companies we with work, from the largest to the smallest, are effectively supported. I welcome the opportunity to hear from you, whether to investigate how our special partnering publications and tools might support your company, or to hear about your comments and suggestions.
Go to the profile of Charles Thiede
Charles Thiede

CEO & Co-Founder, Zapnito

My background is in technology, professional services and digital media. I co-founded Zapnito due to a number of related observations from my time in these sectors: 1) the social web is creating a huge amount of noise 2) expertise that brands have built up over decades is being drowned out and hidden from those that need it 3) these brands are therefore losing their audience to often undeserving and unhelpful sources, and 4) people are finding it harder to access the expertise that they truly value. I therefore decided to create Zapnito, a white-label platform to help trusted brands reclaim their audiences via expert-driven knowledge networks.